Elranatamab reduced the risk of disease progression or death vs standard care in patients with R/R myeloma after prior anti-CD38 therapy and lenalidomide.
|Videos|April 22, 2019
High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia
High-Risk IgVH-Unmutated Chronic Lymphocytic Leukemia
Advertisement
Case:A 62-YearOld Male WithIgVH-Unmutated CLL
- A 62-year-old male presented to PCP with complaints of extreme fatigue and night sweats
- PE: Enlarged mobile lymph nodes bilaterally (~1.5 cm), no palpable spleen or liver
- Laboratory findings:
- WBC; 100 X 109/L
- Lymphocytes; 82 X 109/L
- Hb; 11.2 g/dL
- Platelets; 190 X 109/L
- ANC; 1,950/mm3
- LDH 150 U/L
- Cytogenetic; del(11q),IgVH-unmutated
- β2M, 2.9 mg/L
- Referred to community oncology who diagnosed patient with chronic lymphocytic leukemia
- Patient was started on ibrutinib + rituximab (IR)
- Rai Stage I
Advertisement
Related to this article
Experts weigh continuous BTK inhibitors vs fixed-duration CLL therapy, highlighting TP53/17p risk, patient logistics, and subtle zanubrutinib–acalabrutinib tolerability differences.
The phase 3 VERIFY trial found that rusfertide improved clinical response, reduced phlebotomy requirements, and eased symptom burden in patients with polycythemia vera receiving standard-of-care therapy.
Advertisement
Advertisement
Trending on Targeted Onc
1
ESMO 2026: ADCs and New Combinations Advance Lung Cancer Care
2
340B Contract Pharmacy Case Rekindles Scrutiny Over Program Intent
3
Novel ADCs Show Responses in Ovarian and Cervical Cancer at ESMO 2026
4
Petosemtamab Plus Pembrolizumab Improves OS in PD-L1+ HNSCC
5